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Abstract: Regulatory T cells (Tregs) prevent excessive immune responses and limit immune pathology
upon infections. To fulfill this role in different immune environments elicited by different types of
pathogens, Tregs undergo functional specialization into distinct subsets. During acute type 1 immune
responses, type 1 Tregs are induced and recruited to the site of ongoing Th1 responses to efficiently
control Th1 responses. However, whether a similar specialization process also takes place following
chronic infections is still unknown. In this study, we investigated Treg specialization in persistent
viral infections using lymphocytic choriomeningitis virus (LCMV) and murine cytomegalovirus
(MCMV) infection as models for chronic and latent infections, respectively. We identify CD85k as
a Th1-specific co-inhibitory receptor with sustained expression in persistent viral infections and
show that recombinant CD85k inhibits LCMV-specific effector T cells. Furthermore, expression of the
CD85k ligand ALCAM is induced on LCMV-specific and exhausted T cells during chronic LCMV
infection. Finally, we demonstrate that type 1 Tregs arising during chronic LCMV infection suppress
Th1 effector cells in an ALCAM-dependent manner. These results extend the current knowledge of
Treg specialization from acute to persistent viral infections and reveal an important functional role of
CD85k in Treg-mediated suppression of type 1 immunity.
Keywords: regulatory T cells; chronic viral infection; CD85k; ALCAM
1. Introduction
Regulatory T cells (Tregs) are a distinct subset of CD4+ T helper cells character-
ized by the expression of the transcription factor Foxp3 that play an essential role in
maintaining immune tolerance and homeostasis [1–3]. In addition to inhibiting autoim-
mune responses, Tregs play a critical role in ensuring controlled immune responses
upon pathogen encounter [4]. However, while immune suppression through Tregs limits
immune pathology, it may also promote pathogen persistence [5–8].
Substantial heterogeneity is observed within the Treg pool and ongoing immune
responses induce Treg specialization into different subsets depending on the immune
environment [9–11]. During type 1 immune responses, IFN-γ as well as IL-27 drive the
specialization of Tregs into type 1 Tregs, which are essential for effective control of Th1
responses [9,12,13]. Type 1 Tregs co-express Foxp3 and the Th1 master transcription factor T-
bet, which in turn induces expression of the chemokine receptor CXCR3 [14]. The mirrored
expression of CXCR3 enables type 1 Tregs to migrate to the same inflammatory sites as the
effector Th1 cells and control local immune responses efficiently.
In addition to T-bet and CXCR3, type 1 Tregs also express a set of Th1-specific co-
inhibitory receptors, including Lag-3 and the novel co-inhibitory receptor CD85k (also
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known as LILRB4, ILT3, or gp49D), which are predictive of their suppressive function [15].
CD85k was originally reported as a surface receptor expressed on myeloid cells that renders
DCs tolerogenic [16,17]. Recombinant CD85k has a similar tolerizing effect and binds to
a ligand that is only expressed on T cells upon their activation [18]. This long elusive
ligand has recently been identified as ALCAM (or CD166) [19], enabling further functional
studies on CD85k. While we and others have found CD85k not only being expressed
on tolerogenic DCs but also on Tregs [15,20], it remained unclear whether this molecule
functionally contributes to Treg-mediated suppression, particularly in the context of Th1
responses, where we found it to be specifically induced in Tregs [15].
Acute infections eliciting Th1 responses induce the expansion of type 1 Tregs followed
by contraction, once the infection is resolved [9,12,13,15]. Whether a similar functional
specialization process of Tregs takes place in persistent infections and whether this is
maintained as the pathogen persists is still unknown. Persistent infections, in which the
virus is not cleared from the individual, can be categorized into chronic infections, in
which the virus in continuously produced and latent infections, characterized by the lack of
infectious virus except for episodes of reactivation. Patients with chronic HIV or hepatitis
A and B virus infection and people latently infected with cytomegalovirus (CMV) harbor
elevated Treg frequencies [21–24], suggesting an active role of Tregs during persistent
viral infections. Furthermore, Tregs have been shown to suppress anti-viral responses
and contribute to viral persistence in herpes simplex virus, Friend virus, or murine CMV
(MCMV) infection [6,7,25,26]. Hence, Tregs play an active role during persistent viral
infections, but whether this requires their functional specialization into type 1 Tregs has
not been addressed.
In the present study, we examined and characterized Treg responses in persistent
viral infections, which elicit Th1 immune responses. We show that Tregs isolated from
lymphocytic choriomeningitis virus (LCMV)-infected mice retain an unimpaired suppres-
sive capacity. Furthermore, we describe common phenotypic features of Treg responses
in persistent infections and identify CD85k as a co-inhibitory receptor with sustained
expression in both chronic LCMV and latent MCMV infection. We show that recombinant
CD85k can inhibit LCMV-specific effector T cells and that the CD85k ligand ALCAM is
induced on LCMV-specific effector T cells during chronic LCMV infection. We also found
ALCAM expression to be maintained on exhausted T cells. Finally, we show that type 1
Tregs arising during chronic LCMV infection suppress Th1 effector cells in an ALCAM-
dependent manner. These results extend our current knowledge of Treg specialization
from acute to persistent viral infections and reveal an important functional role of CD85k
in Treg-mediated control of persistent Th1 responses.
2. Results
2.1. Tregs Maintain Suppressive Function during Chronic Infection
Tregs have been shown to contribute to pathogen persistence by inhibiting effector
T cell function [5]. Nevertheless, as effector T cells acquire a dysfunctional phenotype
during chronic LCMV infection [27], we first wanted to confirm that Tregs retain their
suppressive function during chronic infection with LCMV Clone 13. To address this, we
compared the ability of Tregs isolated from naive or chronically LCMV infected mice to
suppress CD4+ Th1 effector cells in an in vitro suppression assay. CD4+GFP+ Tregs from
Foxp3-GFP.KI reporter mice were sorted from naive or chronically LCMV infected mice
(day 30) and co-cultured with CD4+GFP- Th1 effector cells isolated from LCMV-infected
mice and stimulated with anti-CD3. We observed no differences in the ability of Tregs
from naive or chronically infected mice to suppress Th1 effector T cell proliferation or
their secretion of IFN-γ (Figure 1a–c). The in vitro suppressive capacity of Tregs is thus
unimpaired during chronic LCMV infection.







Figure 1. Tregs maintain suppressive function during chronic infection. (a–c) CD4+GFP+ Tregs were sorted from naive
or day 30–40 LCMV Clone 13-infected Foxp3-GFP.KI reporter mice and co-cultured with CD4+GFP- Th1 effector cells
(from LCMV WE-infected mice) stimulated with anti-CD3 (1 µg/mL) and irradiated splenic APCs. After 2 days, proliferation
was determined by [3H]-thymidine incorporation. Treg-mediated suppression of proliferation (a), proliferation (b), and IFN-
γ concentrations in the culture supernatant (c) are displayed (mean ± SD; biological replicates, n = 3; 1 representative
experiment of 3 is shown). (d–f) DEREG and WT control mice were infected with LCMV Clone 13 and injected with
diphtheria toxin on day 10, 12, 14, and 16 post infection to deplete Tregs or as a control. On day 17, spleens were harvested,
Treg frequencies were determined by flow cytometry (d), and frequencies of LCMV-specific T cells were determined in
splenocytes by re-stimulation with LCMV gp33 and gp61 followed by intracellular cytokine staining and flow cytometric
analysis of IFN-γ (e) and TNF-α (f) production by CD8+ or CD4+ T cells (mean ± SD; n = 5–6 (WT) or 4 (DEREG);
1 representative experiment out of 2 is shown). * p < 0.05, **** p < 0.0001; t-Test.
To test their functionality in vivo, we took advantage of DEREG mice, which express
the diphtheria toxin receptor under the control of the Foxp3 promotor and thus allow
for deletion of Tregs through diphtheria toxin administration [28]. DEREG mice were
infected with LCMV Clone 13 and Tregs depleted starting from day 10 post infection,
when chronic infection is already established. In line with previous studies [29], DTR- Tregs
had re-emerged in DEREG mice 7 days after the beginning of Treg depletion, but Treg
numbers remained significantly reduced compared to control animals (Figure 1d). On day
17 post infection (7 days after the beginning of Treg depletion), the effector T cell response
was analyzed, and despite the re-emerging Treg population in DEREG mice (Figure 1d),
a slight increase in the frequency of IFN-γ+ and TNF-α+ CD8+ and CD4+ effector T cells
could be observed following Treg depletion (Figure 1e,f). These results confirm that Tregs
are functional in chronic viral infections and dampen effector T cell responses.
2.2. Tregs Undergo Classical Th1-Specific Specialization in Persistent Infection
During acute Th1 responses, Tregs undergo functional specialization, which is char-
acterized by the co-expression of the Th1 master transcription factor T-bet with Foxp3 as
well as expression of the chemokine receptor CXCR3 [9,12]. However, whether a similar
specialization into type 1 Tregs takes place during persistent infections has not been ad-
dressed. As Tregs isolated from chronically infected mice were functional both in vitro
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and in vivo, we next investigated whether they also undergo functional specialization into
type 1 Tregs during persistent viral infections. To obtain a more comprehensive picture
of phenotypic changes in Tregs during persistent Th1-dominated infections, we not only
analyzed Tregs during chronic LCMV Clone 13 infection but also investigated Tregs follow-
ing MCMV infection, which induces a latent infection. Furthermore, sublingual infections
with Candida albicans strain 101 served as a persistent but Th17-polarized fungal control
infection [30].
Despite a transient decrease of PD-1 upon MCMV infection, Tregs from both LCMV-
and MCMV-infected mice showed robust expression of the co-inhibitory receptors CTLA-4,
PD-1, and TIGIT (Figure S1), which are associated with Treg suppressive function [31–33].
Furthermore, both viral but not fungal C. albicans infections resulted in an increase of
CXCR3+ Tregs (Figure 2a), suggesting that a similar type 1 specialization process as has
been reported in acute infections takes place in persistent infections and may be maintained
in chronic LCMV infection. Although, the frequency of CXCR3+ Tregs starts to decrease
60 days after LCMV infection as, at this point, the virus starts to get cleared due to the
emerging antibody response [34,35]. We next assessed the expression of the co-inhibitory
receptors Lag-3 and CD85k, which are specifically induced in the context of acute type 1
responses [15]. Lag-3, which peaks early in acute Th1 infections [15], was only transiently
upregulated in mice persistently infected with LCMV but not MCMV (Figure 2b). In con-
trast, the frequency of CD85k+ Tregs was robustly induced in both persistent viral infections
(Figure 2b). While expression was maintained in LCMV infection, CD85k was only tran-
siently induced during MCMV infection, and during the latent phase (day 60) only a trend
towards higher CD85k expression could be observed, which did not reach significance.
Importantly, persistent C. albicans infection, which is marked by a Th17 response [36,37],
did not induce Lag-3 or CD85k expression in Tregs (Figure 2b), confirming the specificity
of Lag-3 and CD85k as Th1-specific co-inhibitory receptors on Tregs. This was further
supported by the fact that Lag-3 and CD85k were almost exclusively expressed in CXCR3+
Tregs (Figure 2c,d). Tregs thus undergo specialization into type 1 Tregs during persistent
infection, which is marked by expression of CXCR3 and the Th1-specific co-inhibitory
receptor CD85k and is maintained throughout the course of chronic LCMV but not latent
MCMV infection, suggesting that active viral replication is necessary to maintain increased
levels of CD85k+ type 1 Tregs.
Tregs expressing CD85k are highly suppressive for Th1 effector cells [15]. Given that
CD85k+ Tregs are induced and in the case of chronic LCMV infection even maintained
during viral infection, we hypothesized that the interaction of CD85k on Tregs with its
ligand ALCAM [19] on effector cells could limit the effector T cell response during persistent
infection. To test this hypothesis, we first analyzed ALCAM expression on effector cells
during the latent phase of MCMV infection (day 60). Although we did not observe an
overall increase in ALCAM expression on effector T cells in MCMV-infected animals
(Figure 3a), MCMV-specific T cells (identified by tetramer staining or re-stimulation with
MCMV peptides) expressed higher levels of ALCAM than naïve, tetramer-, or cytokine-
negative T cells (Figure 3b–d). However, the increase in ALCAM was only modest and
comparable in T cells specific for inflationary and non-inflationary epitopes.
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Figure 2. Tregs undergo Th1-specific specialization in persistent viral infection infections. C57BL/6 mice were left naïve
(day 0) or infected with LCMV Clone 13 (blue, 2 × 106 ffu i.v.), MCMV (red, 2 × 105 pfu i.v.), or C. albicans strain 101
(orange, 2.5 × 106 cfu sublingual), and sacrificed 8, 30, and 60 days post infection. Spleens (LCMV, MCMV) or cervical
lymph nodes (C. albicans) were harvested and directly analyzed ex vivo by flow cytometry. (a,b) Representative plots
(left) and summary graphs (right) for frequencies of CXCR3+ (a), Lag-3+, and CD85k+ (b) Foxp3+CD4+ Tregs are depicted.
(c,d) Frequencies of Lag-3+ (c) or CD85k+ (d) cells among CXCR3+ (red) or CXCR3- (grey) Tregs were also determined
in LCMV- and MCMV-infected mice (mean ± SD; biological replicates: naive n = 5–7; LCMV n = 8–12, MCMV n = 8–10,
C. albicans n = 19; pooled data of 2–4 independent experiments). * p < 0.05, **** p < 0.0001, ns: not significant; for comparison
of two or more groups, 2-sided t-Test or one-way ANOVA was used, respectively.
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Figure 3. ALCAM is expressed on MCMV-specific effector T cells. C57BL/6 mice were left naïve
(day 0) or infected with MCMV (2 × 105 pfu i.v.). 60 days post infection, spleens were harvested
and frequencies of ALCAM+ total CD4+ or CD8+ T cells (a) and ALCAM expression within CD8+
T cells stained by the M38-tetramer (b) were determined by flow cytometry. (c,d) Samples were
re-stimulated with peptides of inflationary (c, M38 and M09) or non-inflationary (d, M45 and M25)
MCMV epitopes for 4 h before staining for ALCAM in conjunction with intracellular cytokines
among CD8+ or CD4+ T cells. Summary data (a–d) and representative stainings (b) are displayed
(mean ± SD; biological replicates: naive n = 4, day 60 n = 8). ** p < 0.01, *** p < 0.001, **** p < 0.0001,
ns: not significant; for comparison of two or more groups, 2-sided t-Test or one-way ANOVA was
used, respectively.
Next, we analyzed ALCAM expression during chronic LCMV infection, where we had
observed a sustained increase in CD85k+ type 1 Tregs (Figure 2b). WT B6 mice were infected
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with LCMV clone 13, and ALCAM expression on CD4+ and CD8+ T cells was analyzed
during the acute (day 8) and chronic (day 30) phase of the infection and compared to naïve
mice (day 0). We could indeed observe a steady increase of ALCAM expression in both
T cell populations that was maintained throughout the course of infection (Figure 4a,b).
Furthermore, LCMV-specific re-stimulation of T cells with the immunodominant peptides
gp33 (for CD8+ T cells) and gp61 (for CD4+ T cells) revealed that the frequency of ALCAM+









































































































































































Figure 4. ALCAM is expressed on LCMV-specific effector T cells. C57BL/6 mice were left naïve
(day 0) or infected with LCMV Clone 13 (2 × 106 ffu i.v.). Then, 8 or 30 days post infection, spleens
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were harvested, and frequencies of ALCAM+ total CD4+ or CD8+ T cells were determined by flow
cytometry (a,b). Samples were re-stimulated with LCMV gp33 and gp61 for 4 h before staining
for ALCAM in conjunction with intracellular cytokines and granzyme (c,d) or PD-1 (e,f) among
CD8+ or CD4+ T cells. Summary data (a,c,e) and representative staining (b,d: day 8, f: day 30) are
displayed (mean ± SD; biological replicates: naive n = 4–6, day 8 n = 4, day 30 n = 8, pooled from in
2–3 independent experiments). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns: not significant;
for comparison of multiple groups, two-way ANOVA with multiple comparisons was used.
LCMV-specific effector T cells become exhausted during the later stages of infection
and show impaired cytokine production upon re-stimulation but high expression of the
co-inhibitory receptor PD-1 [38]. We thus also analyzed ALCAM expression on PD-1+
effector T cells at the chronic stage of infection (day 30) and found a significantly higher
proportion of ALCAM+ cells within PD-1+ effector T cells compared to PD-1- controls or
naïve T cells (Figure 4e). ALCAM is thus induced on LCMV-specific effector T cells during
chronic LCMV infection and its expression is maintained on exhausted T cells.
2.4. Type 1 Tregs Limit ALCAM-Expressing Effector T Cells
CD85k expressed on tolerogenic DCs can inhibit T cell proliferation through binding
to its ligand ALCAM [19]. Based on the upregulation of ALCAM on effector cells during
chronic LCMV infection (Figure 4), we next tested whether CD85k expressed on type 1
Tregs could suppress effector T cells during chronic infection. To this end, we infected WT
B6 mice with LCMV Clone 13 to generate ALCAM-expressing effector T cells. On day 8 post
infection, splenocytes were isolated and re-stimulated with the immunodominant LCMV
peptides (gp33 and gp61) or with anti-CD3 with or without the addition of recombinant
CD85k. After 2 days of stimulation, proliferation was determined by 3H-Thymidine
incorporation and cytokine secretion into the supernatant was assessed by cytometric bead
array (Figure 5a–c). Indeed, recombinant CD85k strongly suppressed proliferation of CD4+
as well as CD8+ T cells, confirming that it can inhibit effector T cell expansion during
chronic viral infection (Figure 5a). Furthermore, secretion of IFN-γ and TNF-α was also
strongly impaired in the presence of recombinant CD85k (Figure 5b,c). CD85k is thus able
to potently suppress the expansion and function of effector T cells arising during chronic
LCMV infection.
Finally, we tested whether the CD85k-expressing type 1 Tregs induced upon chronic
LCMV infection suppress effector T cells by engaging ALCAM on these cells. We per-
formed an in vitro suppression assay to determine the ability of type 1 Tregs from chronic
mice to suppress effector T cells from chronically infected WT or ALCAM KO mice.
CXCR3+CD4+GFP+ type 1 Tregs were sorted from Foxp3-GFP.KI reporter mice during the
chronic phase of LCMV infection (day 25) and co-cultured with CD4+ effector T cells from
either WT or ALCAM KO mice also infected with LCMV clone 13 and stimulated with
anti-CD3. In line with our hypothesis, we observed reduced suppression of ALCAM KO
effector T cells by CXCR3+ type 1 Tregs (Figure 5d). CXCR3+ type 1 Tregs also did not exert
enhanced suppression towards ALCAM KO Th1 cells when compared to CXCR3- Tregs
as they did towards WT Th1 cells (Figure 5e and Figure S2). In addition, CXCR3+ type 1
Tregs could not suppress the secretion of IFN-γ by ALCAM KO T cells, while suppression
of IFN-γ secretion was observed in WT Th1 cells (Figure 5f). Taken together, these data
show that type 1 Tregs arising during chronic viral infection suppress effector Th1 cells by
engaging ALCAM.
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–Figure 5. Suppression of effector T cells from chronic infection. (a–c) C57BL/6 mice were
left naïve (day 0) or infected with LCMV Clone 13 (2 × 106 ffu i.v.). Then, 8 days post infec-
tion, spleens were harvested and cells were re-stimulated with anti-CD3 (left), LCMV gp61
(middle), or gp33 (right) in the presence (red) or absence (black) of recombinant CD85k.
After 2 days, proliferation was determined by [3H]-thymidine incorporation (a) and the
secretion of IFN-γ (b) and TNF-α (c) into the culture supernatant was determined by CBA
(mean ± SD; n = 4; 1 representative experiment of 2 is shown). (d–f) CXCR3+CD4+GFP+
and CXCR3-CD4+GFP+ Tregs were sorted from LCMV Clone 13-infected Foxp3-GFP.KI
reporter mice (day 25) and co-cultured with CD4+ Th1 effector cells sorted from C57BL/6
WT mice (filled symbols) or ALCAM-/- mice (open symbols) also infected with LCMV
Clone 13 (day 10). Cells were stimulated with anti-CD3 and irradiated splenic APCs for 2
days before proliferation was determined by [3H]-thymidine incorporation. Treg-mediated
suppression of proliferation (d,e) and IFN-γ concentrations in the culture supernatant
(f) are shown (mean ± SD; n = 3; 1 representative experiment of 2 is shown). * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001, ns: not significant; for comparison of two or more
groups, 2-sided t-Test or one-way ANOVA were used, respectively.
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3. Discussion
In this study, we showed that Tregs undergo functional specialization into type 1
Tregs during persistent viral infection and identified CD85k as a co-inhibitory receptor
with sustained expression in this Treg subset during chronic infection. The CD85k ligand
ALCAM is induced and maintained on virus-specific effector T cells during chronic LCMV
infection and recombinant CD85k can inhibit LCMV-specific effector T cells. Most im-
portantly, type 1 Tregs arising during chronic LCMV infection, which specifically express
CD85k, suppress Th1 effector cells in an ALCAM-dependent manner.
Th1 responses elicited upon acute infectious challenge induce the specialization of
Tregs into T-bet-expressing CXCR3+ type 1 Tregs [9,12]. While expression of T-bet in
inflammation-experienced Treg was shown to be highly stable over time [12], this study
only examined Tregs induced in acute infections, where immune activation and the pres-
ence of polarizing cytokines are transient. We show here that type 1 specialization of
Tregs also takes place in persistent viral infections. Although the specialization into type 1
Tregs could be observed upon both LCMV and MCMV infection, the induction of CXCR3+
Tregs was more pronounced in chronic LCMV infection. These differences may be due
to the nature of the infections, which are characterized by high and sustained antigen
loads in LCMV Clone 13 infection [27] or latency with undetectable virus in the spleen
and sporadic re-activation in persistent MCMV infection [39]. Furthermore, potentially
higher concentrations of the polarizing cytokines IFN-γ or IL-27 could induce a more
pronounced Treg specialization upon LCMV infection. Nevertheless, the frequency of
CD85k+ Tregs was clearly increased in the later phase of both infectious settings, albeit
it was only maintained in chronic and not latent infection. This suggests that active viral
replication and inflammation are necessary to maintain increased levels of CD85k+ type 1
Tregs. As such, it will be interesting to determine whether, like CXCR3, CD85k expression
is also induced by IFN-γ and IL-27 and the transcription factor T-bet or whether additional
factors contribute to the induction of CD85k.
Treg specialization has been reported in the context of type 1, type 2, and type 17
responses and is marked by the mirrored expression of transcription factors and chemokine
receptors in effector and regulatory T cells [9–11]. The expression of corresponding
chemokine receptors allows specialized Tregs to migrate to the same site as the respec-
tive effector T cells and is therefore important for effective immune suppression [9,12].
Nevertheless, how or whether the transcriptional program induced by the lineage-specific
transcription factors may contribute to enhanced or even selective suppressive function is
still largely unclear. Interestingly, the induced deletion of T-bet expression in Tregs had no
immediate effects on overall immune homeostasis, while the ablation of T-bet-expressing
Tregs resulted in a loss of control of Th1 responses and autoimmunity [12]. This suggests
that once the Tregs are properly positioned, T-bet (and CXCR3) are no longer required
for efficient Treg function. Nevertheless, type 1 Tregs induced during acute infections are
more suppressive towards Th1 cells than CXCR3- or naïve Tregs in in vitro suppression
assays, where obviously migration does not play a role [15]. Importantly, this enhanced
suppression was only observed towards Th1 but not naïve CD4+ T cells and thus was not
a result of overall enhanced function but of functional specialization of type 1 Tregs [15].
We have previously reported that Th1-specific co-inhibitory receptors on Tregs, including
CD85k, are predictive of enhanced Th1 suppression [15]. Here, we further extended this
finding and functionally link expression of the CD85k ligand ALCAM with the ability
of Th1 cells to be efficiently suppressed by type 1 Tregs in the setting of a chronic viral
infection.
Interestingly, CD85k is prominently expressed in Tregs that lack the kinase CK2β
and are unable to control Th2 immune responses [20]. The inability of CD85k+ Tregs to
suppress Th2 responses in CK2β-deficient mice further supports a functional contribution
of CD85k in the specific suppression of type 1 immunity. A number of co-inhibitory
receptors, including CTLA-4, Lag-3, and TIGIT, have been shown to contribute to overall
Treg suppressive function [31,32,40]. The results we present here add CD85k to the list of
Int. J. Mol. Sci. 2021, 22, 31 11 of 14
co-inhibitory receptors that contribute to specific Treg-mediated suppression and suggest
it fulfils a context-specific inhibitory role in that it is specifically induced to inhibit type 1
immune responses by binding to its ligand ALCAM on effector T cells.
4. Materials and Methods
4.1. Mice, Pathogens, and Infections
All animal experiments were reviewed and approved by the cantonal veterinary office
of Zurich (licenses ZH119/17, ZH178/17, ZH179/17, ZH115/17, ZH114/17, ZH183/15,
ZH058/20, and ZH166/18) and performed in accordance with Swiss legislation. Mice were
bred and housed at the Laboratory Animal Sciences Center (LASC) Zurich, Switzerland or
the ETH Phenomics Center Zurich, Switzerland. C57BL/6Rj (WT) mice were purchased
from Janvier Laboratories (Saint Berthevin Cedex, France). Foxp3-GFP.KI reporter mice [41],
DEREG mice [28], and ALCAM−/− mice [42] were described previously.
LCMV Clone 13 was propagated on BHK21 cells. MCMV (BAC-derived Smith strain
on a MCK-2-repaired background [43]) was propagated on M2-10B4 cells. C. albicans strain
101 was grown overnight in YPD medium for 15–18 h at 30 ◦C and 180 rpm before infection.
Sex- and age-matched mice, 6–12 weeks of age, were infected i.v. with 2 × 106 ffu LCMV
Clone 13, or 2 × 105 pfu MCMV, or sublingually with 2.5 × 106 C. albicans yeast cells as
described previously [36]. To deplete Tregs, 200 ng of diphtheria toxin (Merck, Buchs,
Switzerland) in PBS were injected i.p. on days 10, 12, 14, and 16 of the experiment.
4.2. Isolation of Leukocytes
For analysis, spleens (from LCMV Clone 13 and MCMV infections) and draining
cervical lymph nodes (C. albicans strain 101 infections) were collected and dissociated by
carefully pushing them through a fine metal mesh or 70-µm cell strainer, respectively. Red
blood cell lysis was performed for spleen samples using ACK buffer (155 mM NH4Cl, 1
mM KHCO3, 0.1 mM NA2EDTA in ddH2O, pH 7.2–7.4) prior to staining for flow cytometry.
4.3. Flow Cytometry
Single-cell suspensions were surface stained with fluorophore-conjugates antibodies
for 20 min, followed by fixation/permeabilization for 45 min using the Foxp3 Staining
Buffer Set (eBioscience, Waltham, MA, USA) for transcription factor staining or 10 min
using the BD Fixation/Permeabilization Solution kit (BD Bioscience, Franklin Lakes, NJ,
USA) for intracellular cytokine staining, followed by intracellular staining for 30–40 min
at room temperature. For intracellular cytokine staining, isolated bulk splenocytes were
re-stimulated using αCD3 (2 µg/mL, 145-2C11, BioXcell, Lebanon, NH, USA), the immun-
odominant LCMV peptides gp61 and gp33 (1 µg/mL; gp61: GLKGPDIYKGVYQFKSVEFD;
gp33: KAVYNFATM), or inflationary (M09, M38) and non-inflationary (M25, M45) MCMV
peptides (1 µg/mL; M09: GYLYIYPSAGNSFD; M25: NHLYETPISATAMVI; M38: SSPPM-
FRV; M45: HGIRNASFI) for 4 h at 37 ◦C in the presence of Brefeldin A (5 µg/mL, Biolegend,
London, UK). Fluorophore-conjugated antibodies against murine CD4 (RM4-5 or GK1.5),
CD8 (53-6.7), Foxp3 (FJK-16s), CXCR3 (CXCR3-173), CD85k (H1.1), LAG-3 (C9B7W), TIGIT
(1G9), PD-1 (J43), CTLA-4 (UC10-4B9), IFN-γ (XMG1.2), TNF-α (MP6-XT22), GranzymeB
(GB12), and ALCAM (eBioALC48) were purchased from Biolegend, eBioscience, or R&D
Systems (Abingdon, UK). MHC Class I tetramers for M38 (Kb restricted) were produced
as described [44], tetramerized by PE-labelled streptavidin, and added during the extra-
cellular staining step. The LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Invitrogen)
was used to exclude dead cells. Counting beads (CountBright, Invitrogen, Waltham, MA,
USA) were added before flow cytometric acquisition to determine absolute cell numbers.
Data were acquired on a BD LSRFortessa or BD FACSCanto II cytometer (BD Biosciences,
Franklin Lakes, NJ, USA) and analyzed using Flowjo Software (Flowjo, LLC, Ashland,
OR, USA). FACS gates were drawn based on isotype control-stained samples for each
experimental group.
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4.4. In Vitro Co-Culture and Treg Suppression Assays
For co-culture assays, splenocytes were stimulated in 96-well plates at 5 × 105 cells/well
with anti-CD3 (1 µg/mL, 145-2C11) or the immunodominant LCMV peptides gp61 and
gp33 (1 mg/mL) for 2 days at 37 ◦C. Where indicated, recombinant CD85k (12.5 µg/mL,
Cloud Clone Corp.) or Tregs were added to the culture. After 2 days, 1 µCi [3H]-thymidine
(PerkinElmer) was added per well for an additional 18–22 h before harvest and quantification
of [3H]-thymidine incorporation.
Suppression assays were performed as described previously [15]. In brief, CD4+ T
cells were enriched from naïve or LCMV-infected (day 25–40, chronic phase) Foxp3-GFP.KI
mice from spleen and peripheral lymph nodes (inguinal, brachial, axillary, cervical) using
anti-CD4-positive selection beads (Mojo, BioLegend). Tregs were then FACS sorted as
CD4+GFP+ cells on a FACSAria III (BD Biosciences). Th1 effector cells were FACS sorted
from spleen and lymph nodes of day 10–12 LCMV WE or LCMV Clone 13-infected Foxp3-
GFP.KI mice as CD4+GFP- cells, respectively. CD4+GFP- effector cells (4 × 104 cells/well)
and CD4+GFP+ Treg cells were co-cultured in triplicates at effector T: Treg cell ratios
of 2:1, 4:1, 8:1, and 16:1 in the presence of soluble anti-CD3 (1 µg/mL, 145-2C11) and
irradiated splenic antigen-presenting cells (APCs) (2 × 105/well) at 37 ◦C. Assays were
performed in DMEM (10% FCS, β-mercaptoethanol (50 mM), sodium pyruvate (1 mM,
Gibco, Waltham, MA, USA), non-essential amino acids (Gibco), MEM vitamins (Gibco),
penicillin (50 U/mL, Gibco), streptomycin (50 µg/mL, Gibco), and glutamine (2 mM,
Gibco)). After 48 h, 1 µCi [3H]-thymidine (PerkinElmer, Schwerzenbach, Switzerland) was
added to each well followed by 18–22 h of additional incubation. Cells were then harvested
and [3H]-thymidine incorporation quantified. Percent suppression = ([mean value of c.p.m.
of CD4+Foxp3− controls]—[c.p.m. of wells effector T and Treg cells]/[mean c.p.m. of
CD4+Foxp3- controls]) × 100.
4.5. Statistical Analysis
Statistical significance was assessed using GraphPad Prism version 8 (GraphPad
Software, San Diego, CA, USA) and Gaussian distribution was assumed for all datasets.
Differences between individual groups were determined using the two-sided t Test or
between more than two groups using one- or two-way ANOVA with multiple comparisons.
Outlier calculation was performed using the ROUT method. Statistical significance values
are indicated as follows: p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).
Supplementary Materials: Supplementary Materials can be found at https://www.mdpi.com/1422
-0067/22/1/31/s1. Figure S1: Treg characterization during chronic infection. Figure S2: Suppression
by type 1 Tregs is ALCAM-dependent.
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